Form D · Biotechnology

Decibel Therapeutics, Inc.

Boston, MA · CIK 0001656536

Offering snapshot reported Nov 12, 2020 · SEC filing

Reported sold
$54.8M
Offering amount: $82.2M
Investors reported
23
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 2, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 12, 2020Initial$54,800,067No comparison23SEC filing
Jan 13, 2017Amendment$32,332,584$24,332,584vs Oct 27, 20153SEC filing
Oct 27, 2015Initial$8,000,000No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-380289

Source: Form D, filed Nov 12, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Troy Brennan Director
Roger Brown Director
Jens Eckstein Director
Neil Exter Director
Steven H. Holtzman Director, Executive
Jeffrey Jonas Director
John J. Keilty Executive
Elisabeth Leiderman Executive
Craig Muir Director
Anthony Philippakis Director
Christine A. Poon Director
Laurence Reid Director, Executive
George Scangos Director
Michael Solomon Executive
Kevin Starr Director
Peter A. Thompson Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1325 Boylston Street Suite 500
Boston, MA, 02215